Scarica l'app Stockscreener
1.26
0.79%
-0.01
Dopo l'orario di chiusura:
1.26
Precedente Chiudi:
$1.27
Aprire:
$1.25
Volume 24 ore:
105.57K
Relative Volume:
0.22
Capitalizzazione di mercato:
$37.65M
Reddito:
-
Utile/perdita netta:
$-64.73M
Rapporto P/E:
-0.45
EPS:
-2.8
Flusso di cassa netto:
$-53.29M
1 W Prestazione:
-11.89%
1M Prestazione:
-3.08%
6M Prestazione:
-39.13%
1 anno Prestazione:
-93.86%
Intervallo 1D:
$1.235
$1.28
Intervallo di 1 settimana:
$1.23
$1.46
Portata 52W:
$0.87
$22.22
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Nome
An 2 Therapeutics Inc
Settore
Industria
Telefono
(650) 331-9090
Indirizzo
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Confronta ANTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.26 | 37.65M | 0 | -64.73M | -53.29M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-09 | Downgrade | Evercore ISI | In-line → Underperform |
| 2024-08-09 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-12 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-01-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
Mostra tutto
An 2 Therapeutics Inc Borsa (ANTX) Ultime notizie
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Applied Therapeutics, Inc. - The Malaysian Reserve
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - GlobeNewswire
Cognition Therapeutics, Inc. Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies - Marketscreener.com
Actuate Therapeutics Announces Positive Interim Phase 2 - GlobeNewswire
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy - GlobeNewswire
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 - GlobeNewswire
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) - Business Wire
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 - Business Wire
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Brea - PR Newswire
Keros Therapeutics Announces Update on the Phase 2 TROPOS Trial - GlobeNewswire
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium - Yahoo Finance
Protara Therapeutics, Inc. Announces Positive Results from the Ongoing Phase 2 Advanced Advanced-2 Trial of TARA-002 in Patients with NMIBC - Marketscreener.com
Nuvig Therapeutics Announces $161 Million Series B Financing and Progression to Phase 2 Development with Novel, Second-Generation Immunomodulator - Business Wire
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment - Yahoo Finance
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies - GlobeNewswire
Empyrean Therapeutics Acquires TLR-2 Antagonist Molecule From Eos Therapies to Advance and Commercialize Breakthrough Cancer Treatment - Weatherford Democrat
Aclaris Therapeutics And 2 Other US Penny Stocks To Watch - Yahoo Finance
Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease - Business Wire
Silence Therapeutics Presents Late-Breaking Phase 2 Zerlasiran Data at 2024 American Heart Association (AHA) Annual Meeting - Business Wire
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study - The Manila Times
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 - GlobeNewswire
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements - GlobeNewswire
Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024 - The Manila Times
Grace Therapeutics And 2 Other US Penny Stocks To Watch - Yahoo Finance
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia - BioSpace
22q11.2 Deletion Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Nobias Therapeutics, Zynerba Pharma, Bausch Health Americas - The Globe and Mail
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - GlobeNewswire
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire
ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes - GlobeNewswire
Cognition Therapeutics Presents Poster of Participant - GlobeNewswire
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - BioSpace
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results - Yahoo Finance
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study - Yahoo Finance
MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain - StockTitan
Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain - GlobeNewswire
Intellia Presents Positive Results from the Phase 2 Study - GlobeNewswire
Viking Therapeutics Inc (VKTX) Q3 2024 Earnings Call Highlights: Strong Financial Position Amid ... - Yahoo Finance
Sinaptica Therapeutics to Present Results of 52-week Phase 2 Study of Precision Neuromodulation for Alzheimer’s Diseases in Oral Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) Conference - Business Wire
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of - GlobeNewswire
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference - Yahoo Finance
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM - GlobeNewswire
Neumora Therapeutics: A Story Of A Class II Biotech (NASDAQ:NMRA) - Seeking Alpha
Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 - GlobeNewswire
Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024 - Yahoo Finance
Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress - GlobeNewswire
Summit Therapeutics Inc (SMMT) Q2 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia - Business Wire
Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease - Business Wire
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. - GlobeNewswire
Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress - StockTitan
Tvardi Therapeutics Announces Presentation of TTI-101 Preclinical Data Providing Mechanistic Rationale for Phase 2 REVERT IPF Clinical Trial at CHEST 2024 - Business Wire
An 2 Therapeutics Inc Azioni (ANTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
An 2 Therapeutics Inc Azioni (ANTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Readnour Robin Shane | Director |
Dec 06 '24 |
Buy |
1.45 |
19,228 |
27,795 |
629,090 |
| Readnour Robin Shane | Director |
Dec 10 '24 |
Buy |
1.49 |
10,000 |
14,930 |
652,573 |
| Readnour Robin Shane | Director |
Nov 27 '24 |
Buy |
1.42 |
50,000 |
70,840 |
622,573 |
| Readnour Robin Shane | Director |
Nov 26 '24 |
Buy |
1.39 |
25,000 |
34,845 |
597,573 |
| Zakrzewski Joseph S | Director |
Nov 27 '24 |
Buy |
1.40 |
2,000 |
2,800 |
125,199 |
| Readnour Robin Shane | Director |
Nov 19 '24 |
Buy |
1.04 |
150,000 |
155,258 |
560,073 |
| Readnour Robin Shane | Director |
Nov 20 '24 |
Buy |
1.16 |
50,000 |
57,870 |
585,073 |
| Zakrzewski Joseph S | Director |
Nov 18 '24 |
Buy |
1.00 |
20,000 |
19,996 |
118,199 |
| Zakrzewski Joseph S | Director |
Nov 19 '24 |
Buy |
1.01 |
5,000 |
5,050 |
123,199 |
| Easom Eric | Chief Executive Officer |
Nov 18 '24 |
Buy |
1.00 |
50,000 |
49,970 |
1,065,766 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):